Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Poseida Therapeutics, Inc. PSTX
$2.85
-$0.22 (-7.62%)
На 18:02, 12 мая 2023
+426.32%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
295057752.00000000
-
week52high
8.82
-
week52low
1.82
-
Revenue
130361508
-
P/E TTM
-4
-
Beta
0.23911500
-
EPS
-0.92000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 09 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 13 мая 2022 г. |
| Cantor Fitzgerald | Overweight | 07 янв 2022 г. | |
| BTIG | Buy | 18 мая 2021 г. | |
| Piper Sandler | Overweight | Overweight | 04 авг 2020 г. |
| HC Wainwright & Co. | Buy | 04 янв 2023 г. | |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Gergen Mark J | D | 330314 | 31819 | 01 февр 2023 г. |
| Ostertag Eric | D | 827320 | 11776 | 01 февр 2023 г. |
| Malin Life Sciences Holdings Ltd | A | 11835673 | 2150000 | 08 авг 2022 г. |
| Ostertag Eric | A | 838824 | 142857 | 08 авг 2022 г. |
| Ostertag Eric | D | 0 | 160696 | 03 авг 2022 г. |
| Collins Cynthia | A | 28500 | 28500 | 16 июн 2022 г. |
| Collins Cynthia | A | 19650 | 19650 | 16 июн 2022 г. |
| BAUM CHARLES M | A | 57000 | 57000 | 16 июн 2022 г. |
| BAUM CHARLES M | A | 39300 | 39300 | 16 июн 2022 г. |
| Schmid John P. | A | 28500 | 28500 | 16 июн 2022 г. |
Новостная лента
Poseida Therapeutics: New Allogeneic Therapies, Leveraging Non-Viral Engineering
Seeking Alpha
06 февр 2023 г. в 16:54
Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatments for Hemophilia A. Poseida is advancing its broad pipeline with its CAR-T portfolio consisting of both autologous and allogeneic/ off-the-shelf products.
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research
27 янв 2023 г. в 10:32
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why
Zacks Investment Research
10 янв 2023 г. в 10:32
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
15 дек 2022 г. в 10:32
Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
PRNewsWire
06 дек 2022 г. в 06:00
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxicity syndrome (ICANS) P-MUC1C-ALLO1 demonstrated encouraging clinical activity including an objective partial response in a breast cancer patient at the lowest dose P-BCMA-ALLO1 demonstrated responses in heavily pre-treated patients with relapsed/refractory multiple myeloma at the lowest CAR-T dose tested including in patients who had failed prior BCMA-targeted therapy and patients with high-risk disease SAN DIEGO , Dec. 6, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022. "These early data being presented at ESMO I-O for our first two fully allogeneic programs reinforce our belief that our technology and approach have the potential to deliver differentiated off-the-shelf CAR-T cell therapies to patients fighting cancer," said Mark Gergen, Chief Executive Officer of Poseida Therapeutics.